Cardiovascular disease (CVD) is the leading cause of death in women as it is for men. However, the awareness of this fact among women is low, who generally and incorrectly think that their leading cause of death is breast cancer. Graham Jackson's erudite review provides the figures about CVD risk in women, examines their risk factors for CVD and discusses possible strategies for prevention and treatment. The large epidemiological study (INTERHEART) of Yusuf and colleagues 1 examined the risk factors for acute myocardial infarction in almost 30,000 men and women of all ages worldwide. The vast majority of risk could be attributed to nine modifiable factors (as shown in Table 3 of the review). Suitable medical management of conditions such as diabetes mellitus and hypertension is clearly essential for CVD prevention. However, lifestyle factors such as smoking, obesity, dietary factors and physical activity are notoriously difficult to modify in a general population, and most clinicians are aware of the difficulty of trying to inflict good health on people in terms of lifestyle modifications. Government-backed public interventions, such as the banning of smoking in public places, are hoped to help improve health, yet at the same time the Government-backed reductions in exercise facilities for school pupils and the constantly increasing availability of junk food will tend to counterbalance such health benefits. One modifiable CVD risk factor unique to women but perhaps not sufficiently emphasized is menopause. The loss of ovarian hormones at the menopause leads to an increase in coronary heart disease (CHD), as highlighted by the doubling of risk seen in women with premature menopause. 2,3 Menopause has adverse effects on several of the CHD risk factors, such as lipids and lipoproteins, glucose and insulin metabolism, body fat distribution, blood pressure and vascular function, while postmenopausal hormone replacement therapy (HRT) use will largely reverse these changes. 4 What then should we consider for the therapeutic primary prevention of CHD in women at increased risk? Drugs such as statins and aspirin may not be effective in this respect, but there is still potential for HRT. 5,6 A follow-up study of the Women's Health Initiative (WHI) 7 showed a clear benefit of estrogen on coronary atheroma as assessed by coronary calcification scores in those women commencing treatment below age 60 years, in keeping with a trend to coronary benefit with HRT seen with decreasing age reported by the WHI investigators, 8 and in contrast to their earliest reports claiming no age effects. 9 Even for the secondary prevention of CHD in women with established disease, HRT benefit should not be completely dismissed providing suitable dosage regimens are used, 10 although in this situation both statins and aspirin are effective. At present, HRT is not given solely for the prevention of coronary disease. But the vast majority of women starting on HRT do so for the relief of menopausal symptoms and the prevention of osteoporosis, and are in their 50s. They can be reassured that HRT is safe and effective 11 and may well benefit their cardiovascular system.
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